PT  - JOURNAL ARTICLE
AU  - Naim Alkhouri
AU  - Nizar N. Zein
TI  - Protease inhibitors: Silver bullets for chronic hepatitis C infection?
AID  - 10.3949/ccjm.79a.11082
DP  - 2012 Mar 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 213--222
VI  - 79
IP  - 3
4099  - http://www.ccjm.org/content/79/3/213.short
4100  - http://www.ccjm.org/content/79/3/213.full
SO  - Cleve Clin J Med2012 Mar 01; 79
AB  - Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.